Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study.

Background: Global Asthma Network (GAN) was established in 2012 as a development to the International Study of Asthma and Allergies in Childhood to improve asthma care globally.

Objective: To survey asthma, allergic rhinitis and atopic dermatitis in primary and secondary school children and to investigate and evaluate its prevalence, severity, management and risk factors in Mexico.

Methods: GAN Phase I is a cross-sectional, multicentre survey carried out in 15 centres corresponding to 14 Mexican cities throughout 2016-2019 using the validated Spanish language version of the GAN Phase I questionnaires.

Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.

Background: Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice.

[Mexican clinical practice guidelines of immunotherapy 2011].

Background: Several international guidelines on immunotherapy exist, but they only apply partially in Mexico. The Mexican guideline of immunotherapy dates from 1998.

Objectives: To establish clinical recommendations and suggestions for Allergy residents and specialists for skin testing and allergen immunotherapy based on evidence and Mexican expert opinion, according to the GRADE system.

Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy.

Background: Several studies have demonstrated the efficacy and safety of sublingual immunotherapy in the treatment of respiratory allergy.

Objective: To determine the frequency of systemic adverse reactions in patients treated with standardized extracts of sublingual immunotherapy.

Methods: Allergic patients with rhinitis with or without asthma and sensitized to at least 1 allergen were included.

[Safety of immunotherapy and skin tests with allergens in children younger than five years].

Background: It has been demonstrated that specific immunotherapy, in addition to its preventive properties, is an effective and safe therapeutic resource for allergic asthma, allergic rhinitis and allergy to insect's venom; however, its use in patients younger than five years has been limited due to the risk of systemic reactions.

Objectives: To know the frequency and severity of systemic reactions in children younger than five years and to know if a greater risk of systemic reactions in this group of age is real.

Patients And Methods: We included 239 patients from one to five years of age with diagnosis of allergic disease and verified its specific sensitivity with skin tests or RAST and were treated with specific immunotherapy.

[Non-fatal systemic reactions caused by immunotherapy and skin tests].

Objective: The frequency and severity of systemic reaction (SR) from skin test (ST) and specific immunotherapy (SIT) in Mexico, have not been published before. In order to know that frequency and severity, a prospective study was performed in the Allergy Clinic at General Hospital of Matamoros from August, 1991 to July, 1996. SR from ST and SIT were monitored.